Orchestra BioMed Holdings, Inc.

NASDAQ:OBIO

Biotechnology

Healthcare
$7.46 +1.16%

+$0.05 today

Market cap
$587.14M
Beta
0.50
P/E (TTM)
-2.8
EPS (TTM)
-$1.42
52W Low $2.20High $5.42

Volume 1.20M

Average 0.22M

OBIO Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Orchestra BioMed Holdings, Inc.NASDAQ: OBIO

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin grows, but more slowly than its trailing trend

Q1 FY2026 selling, general & admin of $6.34M rose 1.3% year over year, behind the +11.1% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 13.0% from the prior quarter. Over 3 fiscal years it compounded at +24.6% a year.

Context

  • Selling, general & admin amounted to 80.4% of revenue in FY2025, down 826.8 pp from a year earlier.
  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 6 analysts of $906.32K (-96.6%) for the fiscal year ending Dec 2026, a slowdown from the +12.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$6.34M-13.0% QoQ
Last fiscal yearDec 2025
$26.91M+12.5% YoY
LTMMar 2026
$26.99M+11.1% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.3%-95.2%-96.4 pp
1 year+12.5%-96.6%-109.1 pp
3-year CAGR+24.6%+4.6%-20.0 pp
5-year CAGR+53.5%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
26.91M USD
Year-over-year change
+12.5%
4-year CAGR
+35.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How OBIO compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +11.1% is the 6th highest of 11, against a peer median of +6.6%.
  • Selling, general & admin amounts to 82.5% of revenue for OBIO, versus a peer median of 234.0%.
OBIO Competitors
Selling, General & Admin for OBIO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IVVDInvivyd, Inc.LTM Mar 2026$74.78M USD+14.7%+12.5%133.9%
IVAInventiva S.A.FY2025€53.89M EUR+215.2%+51.5%1202.1%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$38.28M USD-25.4%-1.1%55.3%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$36.25M USD-1.5%-0.1%323.5%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$26.99M USD+11.1%+24.6%82.5%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$24.19M USD+23.5%+3.4%41000.0%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$23.71M USD-4.5%+3.4%10537.3%
TARAProtara Therapeutics, Inc.LTM Mar 2026$23.01M USD+25.6%+1.9%—
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$21.38M USD-22.5%-9.9%127.9%
PYXSPyxis Oncology, Inc.LTM Mar 2026$20.02M USD-13.1%-15.9%144.4%
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$17.83M USD+52.6%+62.5%—
Peer median (excluding OBIO) —+6.6%+2.6%234.0%

Competitors are the stored peer set for OBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue(782K)3.53M2.76M2.64M33.48M
Cost of Revenue199K322K186K204K190K
Gross Profit(981K)3.21M2.57M2.43M33.29M
Gross Margin125.4%90.9%93.3%92.3%99.4%
Research & Development12.89M21.95M33.82M42.8M58.19M
Selling, General & Admin7.93M13.92M20.26M23.93M26.91M
Operating Expenses20.82M35.87M54.08M66.74M85.1M
Depreciation & Amortization181K222K287K308K327K
EBITDA(21.91M)(33.39M)(48.83M)(60.72M)(51.23M)
EBITDA Margin2801.3%-945.0%-1769.3%-2301.6%-153.0%
Operating Income(21.8M)(32.66M)(51.51M)(64.3M)(51.81M)
Operating Margin2787.6%-924.3%-1866.2%-2437.5%-154.7%
Interest Income050K3.85M3.36M0
Interest Expense927K0001.15M
Other Income / Expenses(1.22M)(951K)2.39M3.28M(894K)
Income Before Tax(23.01M)(33.61M)(49.12M)(61.02M)(52.7M)
Pre-Tax Margin2943.0%-951.3%-1779.7%-2313.3%-157.4%
Income Tax Expense00000
Net Income(23.01M)(33.61M)(49.12M)(61.02M)(52.7M)
Net Margin2943.0%-951.3%-1779.7%-2313.3%-157.4%
EPS (Basic)(0.02)(1.32)(1.48)(1.66)(1.38)
EPS (Diluted)(0.02)(1.32)(1.48)(1.66)(1.38)
Weighted Avg Shares20.45M25.47M33.23M36.82M38.39M
Weighted Avg Shares (Diluted)20.45M25.47M33.23M36.82M38.39M

Orchestra BioMed Holdings, Inc.

NASDAQ:OBIO

Intrinsic Alpha fair value

Locked

Current Price

$7.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.